These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23447566)

  • 1. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells.
    McKee AS; Burchill MA; Munks MW; Jin L; Kappler JW; Friedman RS; Jacobelli J; Marrack P
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):E1122-31. PubMed ID: 23447566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contamination of DNase Preparations Confounds Analysis of the Role of DNA in Alum-Adjuvanted Vaccines.
    Noges LE; White J; Cambier JC; Kappler JW; Marrack P
    J Immunol; 2016 Aug; 197(4):1221-30. PubMed ID: 27357147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro.
    Ghimire TR; Benson RA; Garside P; Brewer JM
    Immunol Lett; 2012 Sep; 147(1-2):55-62. PubMed ID: 22732235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
    Liang F; Lindgren G; Sandgren KJ; Thompson EA; Francica JR; Seubert A; De Gregorio E; Barnett S; O'Hagan DT; Sullivan NJ; Koup RA; Seder RA; Loré K
    Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.
    Kool M; Soullié T; van Nimwegen M; Willart MA; Muskens F; Jung S; Hoogsteden HC; Hammad H; Lambrecht BN
    J Exp Med; 2008 Apr; 205(4):869-82. PubMed ID: 18362170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen depot is not required for alum adjuvanticity.
    Hutchison S; Benson RA; Gibson VB; Pollock AH; Garside P; Brewer JM
    FASEB J; 2012 Mar; 26(3):1272-9. PubMed ID: 22106367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.
    Gerner MY; Mescher MF
    J Immunol; 2009 Mar; 182(5):2726-37. PubMed ID: 19234167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Syk-NFAT-IL-2 Pathway in Dendritic Cells Is Required for Optimal Sterile Immunity Elicited by Alum Adjuvants.
    Khameneh HJ; Ho AW; Spreafico R; Derks H; Quek HQ; Mortellaro A
    J Immunol; 2017 Jan; 198(1):196-204. PubMed ID: 27895176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P; Brocker T
    J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alum-functionalized graphene oxide nanocomplexes for effective anticancer vaccination.
    Wang X; Cao F; Yan M; Liu Y; Zhu X; Sun H; Ma G
    Acta Biomater; 2019 Jan; 83():390-399. PubMed ID: 30448435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection.
    Mwangi W; Brown WC; Splitter GA; Zhuang Y; Kegerreis K; Palmer GH
    J Leukoc Biol; 2005 Aug; 78(2):401-11. PubMed ID: 15857936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
    Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
    J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
    Sokolovska A; Hem SL; HogenEsch H
    Vaccine; 2007 Jun; 25(23):4575-85. PubMed ID: 17485153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.
    Cho KJ; Ishido S; Eisenlohr LC; Roche PA
    J Immunol; 2020 Mar; 204(6):1621-1629. PubMed ID: 31996461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells.
    Kamath AT; Valenti MP; Rochat AF; Agger EM; Lingnau K; von Gabain A; Andersen P; Lambert PH; Siegrist CA
    Eur J Immunol; 2008 May; 38(5):1247-56. PubMed ID: 18412160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of multivesicular body vesicles does not affect major histocompatibility complex (MHC) class II-peptide complex formation and antigen presentation by dendritic cells.
    Bosch B; Berger AC; Khandelwal S; Heipertz EL; Scharf B; Santambrogio L; Roche PA
    J Biol Chem; 2013 Aug; 288(34):24286-92. PubMed ID: 23846690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.